Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Prognostic Impact of Adjuvant Therapy in Primary Hepatic Sarcomatoid Carcinoma — Stella

Recruiting

Back to Sarcomatoid Carcinoma trials

Trial locations(1 site)

China

West China Hospital, Chengdu, Sichuan

Key details

Sponsor

West China Hospital

Enrollment target

~50 participants

Started

April 2025

Primary completion

May 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated April 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov